The diagnosis concluded that this was not a temporary market volatility, but a structural turning point in the shift of the industry from “technology windfall” to “cost struggle”. The core indicator on the test list is extremely clear: in 2025, the volume of vaccine production increased by 130. 27 per cent over the same period, but the income from vaccine operations was only $457 million, less than the peak of 2022 (8,492 million). The backlog of surrogate giants with intellectual flying biological stocks amounts to 4. 209 million, with a projected loss of over $10 billion in 2025。
The industry is experiencing severe loss of blood through “volume price increases”, and oversupply is a corollary of the combination of multiple causes。
The supply side of the “capacity competition” hit the demand side of the “growth ceiling”
The cause of the disease comes first from a serious mismatch between supply and demand。
In 2024, the number of new hpv vaccinations in the country fell by 52 per cent in comparison with the same year, and demand growth fell sharply。
When the supply curve moves right at a fast pace and the demand curve has been flattened ahead of time, the “lake of cypress”, which has an imbalance between supply and demand, quickly emerges。
The precision cutting of the policy “scalter” completely changed the logic of market payments
If the mismatch between supply and demand is a chronic disease, the policy adjustment in 2025 is the key surgery that causes acute onset。
For businesses such as vantaa biology, this means that the māori rate for single vaccines has dropped sharply from over 90 per cent to less than 30 per cent at peak, and that “price-for-money” has changed to “volume gain loss”。
The policy is intended to improve the accessibility of vaccines, but its short-term effect is to completely reshape payment systems, drive businesses from high-profit self-financing markets to low-profit, if not non-profit, government procurement tracks, while freezing large-scale market demand。
The “inner factors” of the enterprise strategy magnifies the damage caused by external shocks power
In the face of dramatic changes in the external environment, the structural weaknesses of the industry itself have been exposed, a more deadly cause of disease。
Intellectual flying organisms, on the other hand, are over-dependent on the nine-price proxy import, and stocks and losses are concentrated under the dual shock of domestic substitution and saturation of demand. Their plight reveals the risks of the business model of the industry “an egg in a basket”。
Industry forecast: from "pushing bulls" to the brutal "step out"
Is this business gonna be okay? The answer is: there will be recovery, but the pattern will be completely reshaped. It must be seen later in a hierarchy:
The next nine-priced products of enterprises such as the conservatives will soon be on the market, and the tracks will be rapidly crowded, leaving a short profit window for the pioneers。
In conclusion, the oversupply of the hpv vaccine is the result of three external forces, namely, expansion of supply, peak demand, and dramatic policy changes, which overlap with a single industry's own product structure and inadequate strategic prognosis. The golden age of industry is over and the future will be a new cycle of combined strength, cost control and strategic endurance。
